These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 29235884)

  • 1. Cost per successfully treated patient for vortioxetine versus duloxetine in adults with major depressive disorder: an analysis of the complete symptoms of depression and functional outcome.
    Christensen MC; Munro V
    Curr Med Res Opin; 2018 Apr; 34(4):593-600. PubMed ID: 29235884
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vortioxetine improves symptomatic and functional outcomes in major depressive disorder: A novel dual outcome measure in depressive disorders.
    Christensen MC; Loft H; McIntyre RS
    J Affect Disord; 2018 Feb; 227():787-794. PubMed ID: 29689693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Successfully treated patients with vortioxetine versus venlafaxine: a simplified cost-effectiveness analysis based on a head-to-head study in Asian patients with major depressive disorder.
    Wang G; Zhao K; Reynaud-Mougin C; Loft H; Ren H; Eriksen HF; Ettrup A
    Curr Med Res Opin; 2020 May; 36(5):875-882. PubMed ID: 31990207
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of vortioxetine on functional capacity across different levels of functional impairment in patients with major depressive disorder: a University of California, San Diego Performance-based Skills Assessment (UPSA) analysis.
    Jacobson W; Zhong W; Nomikos GG; Christensen MC; Kurre Olsen C; Harvey PD
    Curr Med Res Opin; 2020 Jan; 36(1):117-124. PubMed ID: 31422713
    [No Abstract]   [Full Text] [Related]  

  • 5. Escitalopram and duloxetine in major depressive disorder: a pharmacoeconomic comparison using UK cost data.
    Wade AG; Fernández JL; François C; Hansen K; Danchenko N; Despiegel N
    Pharmacoeconomics; 2008; 26(11):969-81. PubMed ID: 18850765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive improvement in late-life depression treated with vortioxetine and duloxetine in an eight-week randomized controlled trial: The role of age at first onset and change in depressive symptoms.
    Xue L; Bocharova M; Young AH; Aarsland D
    J Affect Disord; 2024 Sep; 361():74-81. PubMed ID: 38838790
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vortioxetine versus Duloxetine in the Treatment of Patients with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials.
    Li G; Wang X; Ma D
    Clin Drug Investig; 2016 Jul; 36(7):509-17. PubMed ID: 27067232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Placebo-Controlled, Active-Reference, Double-Blind, Flexible-Dose Study of the Efficacy of Vortioxetine on Cognitive Function in Major Depressive Disorder.
    Mahableshwarkar AR; Zajecka J; Jacobson W; Chen Y; Keefe RS
    Neuropsychopharmacology; 2015 Jul; 40(8):2025-37. PubMed ID: 25687662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed.
    Citrome L
    J Affect Disord; 2016 May; 196():225-33. PubMed ID: 26938965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determination of a clinically important difference and definition of a responder threshold for the UCSD performance-based skills assessment (UPSA) in patients with major depressive disorder.
    Harvey PD; Jacobson W; Zhong W; Nomikos GG; Cronquist Christensen M; Kurre Olsen C; Merikle E
    J Affect Disord; 2017 Apr; 213():105-111. PubMed ID: 28213121
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of vortioxetine on cognitive performance in working patients with major depressive disorder: A short-term, randomized, double-blind, exploratory study.
    Baune BT; Sluth LB; Olsen CK
    J Affect Disord; 2018 Mar; 229():421-428. PubMed ID: 29331703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Subgroup Analysis of the Impact of Vortioxetine on Functional Capacity, as Measured by UPSA, in Patients with Major Depressive Disorder and Subjective Cognitive Dysfunction.
    Keefe RSE; Nomikos G; Zhong W; Christensen MC; Jacobson W
    Int J Neuropsychopharmacol; 2018 May; 21(5):442-447. PubMed ID: 29546401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder.
    Khan A; Bose A; Alexopoulos GS; Gommoll C; Li D; Gandhi C
    Clin Drug Investig; 2007; 27(7):481-92. PubMed ID: 17563128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind trial of 2.5 mg and 5 mg vortioxetine (Lu AA21004) versus placebo for 8 weeks in adults with major depressive disorder.
    Mahableshwarkar AR; Jacobsen PL; Chen Y
    Curr Med Res Opin; 2013 Mar; 29(3):217-26. PubMed ID: 23252878
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled 6-wk trial of the efficacy and tolerability of 5 mg vortioxetine in adults with major depressive disorder.
    Jain R; Mahableshwarkar AR; Jacobsen PL; Chen Y; Thase ME
    Int J Neuropsychopharmacol; 2013 Mar; 16(2):313-21. PubMed ID: 22963932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effects of vortioxetine on cognitive dysfunction in patients with inadequate response to current antidepressants in major depressive disorder: A short-term, randomized, double-blind, exploratory study versus escitalopram.
    Vieta E; Sluth LB; Olsen CK
    J Affect Disord; 2018 Feb; 227():803-809. PubMed ID: 29673132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label Pilot Study of Duloxetine in Patients With Irritable Bowel Syndrome and Comorbid Major Depressive Disorder.
    Lewis-Fernández R; Lam P; Lucak S; Galfalvy H; Jackson E; Fried J; Rosario M; de la Cruz AA; Sánchez-Lacay A; Díaz S; Schneier F
    J Clin Psychopharmacol; 2016 Dec; 36(6):710-715. PubMed ID: 27755218
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the University of California San Diego Performance-based Skills Assessment (UPSA) in major depressive disorder: Replication and extension of initial findings.
    Christensen MC; Sluth LB; McIntyre RS
    J Affect Disord; 2019 Feb; 245():508-516. PubMed ID: 30439678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between cognitive function and performance on effort based decision making in patients with major depressive disorder treated with Vortioxetine.
    Subramaniapillai M; Mansur RB; Zuckerman H; Park C; Lee Y; Iacobucci M; Cao B; Ho R; Lin K; Phan L; McIntyre RS
    Compr Psychiatry; 2019 Oct; 94():152113. PubMed ID: 31404802
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized placebo-controlled trial of duloxetine in patients with major depressive disorder and associated painful physical symptoms.
    Gaynor PJ; Gopal M; Zheng W; Martinez JM; Robinson MJ; Marangell LB
    Curr Med Res Opin; 2011 Oct; 27(10):1849-58. PubMed ID: 21838411
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.